170 related articles for article (PubMed ID: 18979098)
1. Adoptive transfer of HER2/neu-specific T cells expanded with alternating gamma chain cytokines mediate tumor regression when combined with the depletion of myeloid-derived suppressor cells.
Morales JK; Kmieciak M; Graham L; Feldmesser M; Bear HD; Manjili MH
Cancer Immunol Immunother; 2009 Jun; 58(6):941-53. PubMed ID: 18979098
[TBL] [Abstract][Full Text] [Related]
2. The collaboration of both humoral and cellular HER-2/neu-targeted immune responses is required for the complete eradication of HER-2/neu-expressing tumors.
Reilly RT; Machiels JP; Emens LA; Ercolini AM; Okoye FI; Lei RY; Weintraub D; Jaffee EM
Cancer Res; 2001 Feb; 61(3):880-3. PubMed ID: 11221874
[TBL] [Abstract][Full Text] [Related]
3. Activated NKT cells and NK cells render T cells resistant to myeloid-derived suppressor cells and result in an effective adoptive cellular therapy against breast cancer in the FVBN202 transgenic mouse.
Kmieciak M; Basu D; Payne KK; Toor A; Yacoub A; Wang XY; Smith L; Bear HD; Manjili MH
J Immunol; 2011 Jul; 187(2):708-17. PubMed ID: 21670315
[TBL] [Abstract][Full Text] [Related]
4. Expansion of HER2/neu-specific T cells ex vivo following immunization with a HER2/neu peptide-based vaccine.
Knutson KL; Disis ML
Clin Breast Cancer; 2001 Apr; 2(1):73-9. PubMed ID: 11899386
[TBL] [Abstract][Full Text] [Related]
5. Potent CD4+ T-cell epitope P30 enhances HER2/neu-engineered dendritic cell-induced immunity against Tg1-1 breast cancer in transgenic FVBneuN mice by enhanced CD4+ T-cell-stimulated CTL responses.
Xie Y; Chen Y; Ahmed KA; Li W; Ahmed S; Sami A; Chibbar R; Tang X; Tao M; Xu J; Xiang J
Cancer Gene Ther; 2013 Oct; 20(10):590-8. PubMed ID: 24052129
[TBL] [Abstract][Full Text] [Related]
6. Targeted delivery of tumor antigens to activated dendritic cells via CD11c molecules induces potent antitumor immunity in mice.
Wei H; Wang S; Zhang D; Hou S; Qian W; Li B; Guo H; Kou G; He J; Wang H; Guo Y
Clin Cancer Res; 2009 Jul; 15(14):4612-21. PubMed ID: 19584156
[TBL] [Abstract][Full Text] [Related]
7. Spontaneous mammary carcinomas fail to induce an immune response in syngeneic FVBN202 neu transgenic mice.
Kurt RA; Whitaker R; Baher A; Seung S; Urba WJ
Int J Cancer; 2000 Sep; 87(5):688-94. PubMed ID: 10925363
[TBL] [Abstract][Full Text] [Related]
8. Peripheral blood mononuclear cells of patients with breast cancer can be reprogrammed to enhance anti-HER-2/neu reactivity and overcome myeloid-derived suppressor cells.
Payne KK; Zoon CK; Wan W; Marlar K; Keim RC; Kenari MN; Kazim AL; Bear HD; Manjili MH
Breast Cancer Res Treat; 2013 Nov; 142(1):45-57. PubMed ID: 24197563
[TBL] [Abstract][Full Text] [Related]
9. Bryostatin 1/ionomycin (B/I) ex vivo stimulation preferentially activates L-selectinlow tumor-sensitized lymphocytes.
Chin CS; Miller CH; Graham L; Parviz M; Zacur S; Patel B; Duong A; Bear HD
Int Immunol; 2004 Sep; 16(9):1283-94. PubMed ID: 15262898
[TBL] [Abstract][Full Text] [Related]
10. The Antitumor Efficacy of IL2/IL21-Cultured Polyfunctional Neu-Specific T Cells Is TNFα/IL17 Dependent.
Phan-Lai V; Dang Y; Gad E; Childs J; Disis ML
Clin Cancer Res; 2016 May; 22(9):2207-16. PubMed ID: 26660518
[TBL] [Abstract][Full Text] [Related]
11. IL-15/IL-15Rα Heterodimeric Complex as Cancer Immunotherapy in Murine Breast Cancer Models.
Guo S; Smeltz RB; Nanajian A; Heller R
Front Immunol; 2020; 11():614667. PubMed ID: 33628206
[TBL] [Abstract][Full Text] [Related]
12. Tumor antigen-specific T-cell expansion is greatly facilitated by in vivo priming.
Dang Y; Knutson KL; Goodell V; dela Rosa C; Salazar LG; Higgins D; Childs J; Disis ML
Clin Cancer Res; 2007 Mar; 13(6):1883-91. PubMed ID: 17363545
[TBL] [Abstract][Full Text] [Related]
13. HER-2/neu is a tumor rejection target in tolerized HER-2/neu transgenic mice.
Reilly RT; Gottlieb MB; Ercolini AM; Machiels JP; Kane CE; Okoye FI; Muller WJ; Dixon KH; Jaffee EM
Cancer Res; 2000 Jul; 60(13):3569-76. PubMed ID: 10910070
[TBL] [Abstract][Full Text] [Related]
14. Signatures associated with rejection or recurrence in HER-2/neu-positive mammary tumors.
Worschech A; Kmieciak M; Knutson KL; Bear HD; Szalay AA; Wang E; Marincola FM; Manjili MH
Cancer Res; 2008 Apr; 68(7):2436-46. PubMed ID: 18381452
[TBL] [Abstract][Full Text] [Related]
15. Regression of experimental medulloblastoma following transfer of HER2-specific T cells.
Ahmed N; Ratnayake M; Savoldo B; Perlaky L; Dotti G; Wels WS; Bhattacharjee MB; Gilbertson RJ; Shine HD; Weiss HL; Rooney CM; Heslop HE; Gottschalk S
Cancer Res; 2007 Jun; 67(12):5957-64. PubMed ID: 17575166
[TBL] [Abstract][Full Text] [Related]
16. Interleukin-15 and its receptor augment dendritic cell vaccination against the neu oncogene through the induction of antibodies partially independent of CD4 help.
Steel JC; Ramlogan CA; Yu P; Sakai Y; Forni G; Waldmann TA; Morris JC
Cancer Res; 2010 Feb; 70(3):1072-81. PubMed ID: 20086176
[TBL] [Abstract][Full Text] [Related]
17. IL-7 + IL-15 are superior to IL-2 for the ex vivo expansion of 4T1 mammary carcinoma-specific T cells with greater efficacy against tumors in vivo.
Cha E; Graham L; Manjili MH; Bear HD
Breast Cancer Res Treat; 2010 Jul; 122(2):359-69. PubMed ID: 19826947
[TBL] [Abstract][Full Text] [Related]
18. CD8+ T cells induce complete regression of advanced ovarian cancers by an interleukin (IL)-2/IL-15 dependent mechanism.
Yang T; Wall EM; Milne K; Theiss P; Watson P; Nelson BH
Clin Cancer Res; 2007 Dec; 13(23):7172-80. PubMed ID: 18056198
[TBL] [Abstract][Full Text] [Related]
19. T cells conditioned with MDSC show an increased anti-tumor activity after adoptive T cell based immunotherapy.
Raber PL; Sierra RA; Thevenot PT; Shuzhong Z; Wyczechowska DD; Kumai T; Celis E; Rodriguez PC
Oncotarget; 2016 Apr; 7(14):17565-78. PubMed ID: 27007050
[TBL] [Abstract][Full Text] [Related]
20. IL-12 enhances the generation of tumour antigen-specific Th1 CD4 T cells during ex vivo expansion.
Knutson KL; Disis ML
Clin Exp Immunol; 2004 Feb; 135(2):322-9. PubMed ID: 14738463
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
